EISAI E2609-G000-301

Drug Development Trials

About the trial

Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease.

View study